Skip to search formSkip to main contentSkip to account menu

GC4419

National Institutes of Health

Related topics

Related topics

2 relations
M40403

Broader (1)

imisopasem manganese

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients treated with radiation and cisplatin.
12071Background: Nephrotoxicity is a major complication of platinum-based chemotherapy and ranges in incidence from 31-68%. The… 
2020
2020
Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.
TPS4670Background: Local progression causes up to 30% of deaths from pancreatic cancer (PC) and is also a significant source of… 
2020
2020
Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
2019
2019
Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.
TPS4164 Background: Local progression causes up to 30% of deaths from pancreatic cancer (PC) and is also a significant source of… 
2019
2019
Abstract 2922: The radioprotector GC4419 enhances the response of squamous cell carcinoma of the head and neck tumors to ionizing radiation and enhances radioimmune therapy
Locoregional recurrence (LRR) is the major cause of morbidity and mortality in patients with squamous cell carcinoma of the head… 
2018
2018
Abstract 667: The radioprotector GC4419 ameliorates radiation induced lung fibrosis while enhancing the response of non-small cell lung cancer tumors to high dose per fraction radiation exposures
Stereotactic Ablative Radiotherapy (SAbR) has revolutionized the treatment of non-small cell lung cancer (NSCLC). Despite these… 
2018
2018
A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients (pts) with Locally Advanced…
2016
2016
Phase Ib trial of superoxide (SO) dismutase (SOD) mimetic GC4419 to reduce chemoradiotherapy (CRT)-induced oral mucositis (OM) in patients (pts) with oral cavity or oropharyngeal carcinoma (OCC).
10120Background: CRT-induced SO significantly contributes to OM initiation. GC4419 (MW=483) specifically mimics SOD’s dismutation… 
2016
2016
Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC)
2016
2016
Phase 1b Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy (CRT)-Induced Oral Mucositis (OM) in Patients (pts) With Oral Cavity or Oropharyngeal Carcinoma (OCC)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)